FabrÃ-cio A Moreira

List of Publications by Year
in descending order

67	2,787	236833	182361
papers	citations	25 h-index	51 g-index

68	68	68	3403
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology, 2008, 54, 141-150.	2.0	238
2	Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 133-144.	2.2	229
3	The psychiatric side-effects of rimonabant. Revista Brasileira De Psiquiatria, 2009, 31, 145-153.	0.9	191
4	Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 1466-1471.	2.5	168
5	Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. European Journal of Pharmacology, 2005, 512, 199-205.	1.7	164
6	Cannabinoids and Anxiety. Current Topics in Behavioral Neurosciences, 2009, 2, 429-450.	0.8	146
7	Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Frontiers in Behavioral Neuroscience, 2011, 5, 63.	1.0	101
8	Opposing Roles for Cannabinoid Receptor Type-1 (CB1) and Transient Receptor Potential Vanilloid Type-1 Channel (TRPV1) on the Modulation of Panic-Like Responses in Rats. Neuropsychopharmacology, 2012, 37, 478-486.	2.8	97
9	Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxietyâ€”two sides of one coin?. Neuroscience, 2012, 204, 186-192.	1.1	92
10	Modulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray. European Neuropsychopharmacology, 2009, 19, 188-195.	0.3	90
11	Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels. Epilepsy and Behavior, 2017, 75, 29-35.	0.9	82
12	Effects of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole-induced seizure and electroencephalographic activity in rats. Epilepsy Research, 2013, 104, 195-202.	0.8	70
13	Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Possible role of the mTOR pathway and reduction in glutamate release. NeuroToxicology, 2015, 50, 116-121.	1.4	70
14	The endocannabinoid and endovanilloid systems interact in the rat prelimbic medial prefrontal cortex to control anxiety-like behavior. Neuropharmacology, 2012, 63, 202-210.	2.0	68
15	Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. European Journal of Pharmacology, 2008, 578, 222-227.	1.7	64
16	A role for the endocannabinoid system in exercise-induced spatial memory enhancement in mice. Hippocampus, 2014, 24, 79-88.	0.9	58
17	Modeling panic disorder in rodents. Cell and Tissue Research, 2013, 354, 119-125.	1.5	53
18	Effects of early or late prenatal immune activation in mice on behavioral and neuroanatomical abnormalities relevant to schizophrenia in the adulthood. International Journal of Developmental Neuroscience, 2017, 58, 1-8.	0.7	45

#	Article	IF	Citations
19	Animal models for predicting the efficacy and side effects of antipsychotic drugs. Revista Brasileira De Psiquiatria, 2013, 35, S132-S139.	0.9	41
20	Reduced anxiety-like behavior in transgenic rats with chronically overproduction of angiotensin-(1â€“7): Role of the Mas receptor. Behavioural Brain Research, 2017, 331, 193-198.	1.2	39
21	Opposing roles of CB₁ and CB₂ cannabinoid receptors in the stimulant and rewarding effects of cocaine. British Journal of Pharmacology, 2019, 176, 1541-1551.	2.7	36
22	Endocannabinoids and striatal function. Behavioural Pharmacology, 2015, 26, 59-72.	0.8	35
23	Anxiolytic- and antidepressant-like effects of angiotensin-(1â€“7) in hypertensive transgenic (mRen2)27 rats. Clinical Science, 2016, 130, 1247-1255.	1.8	34
24	Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs. Behavioural Pharmacology, 2014, 25, 425-433.	0.8	33
25	Is there a role for cannabidiol in psychiatry?. World Journal of Biological Psychiatry, 2019, 20, 101-116.	1.3	31
26	Dopamine receptor partial agonists and addiction. European Journal of Pharmacology, 2015, 752, 112-115.	1.7	28
27	N-arachidonoyl-serotonin, a dual FAAH and TRPV1 blocker, inhibits the retrieval of contextual fear memory: Role of the cannabinoid CB1 receptor in the dorsal hippocampus. Journal of Psychopharmacology, 2017, 31, 750-756.	2.0	28
28	Anti-aversive effects of the atypical antipsychotic, aripiprazole, in animal models of anxiety. Journal of Psychopharmacology, 2011, 25, 801-807.	2.0	27
29	The roles of cannabinoid CB1 and CB2 receptors in cocaine-induced behavioral sensitization and conditioned place preference in mice. Psychopharmacology, 2020, 237, 385-394.	1.5	27
30	Effects of compounds that interfere with the endocannabinoid system on behaviors predictive of anxiolytic and panicolytic activities in the elevated T-maze. Pharmacology Biochemistry and Behavior, 2013, 110, 33-39.	1.3	26
31	Effects of Aripiprazole, an Atypical Antipsychotic, on the Motor Alterations Induced by Acute Ethanol Administration in Mice. Basic and Clinical Pharmacology and Toxicology, 2013, 112, 319-324.	1.2	22
32	Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report. Human Psychopharmacology, 2014, 29, 94-99.	0.7	22
33	Enhancement of endocannabinoid signaling protects against cocaine-induced neurotoxicity. Toxicology and Applied Pharmacology, 2015, 286, 178-187.	1.3	22
34	The antipsychotic aripiprazole induces antinociceptive effects: Possible role of peripheral dopamine D2 and serotonin 5-HT1A receptors. European Journal of Pharmacology, 2015, 765, 300-306.	1.7	21
35	The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice. European Journal of Pharmacology, 2014, 742, 139-144.	1.7	20
36	Anticonvulsant Effects of Nâ€Arachidonoylâ€Serotonin, a Dual Fatty Acid Amide Hydrolase Enzyme and Transient Receptor Potential Vanilloid Typeâ€1 (<scp>TRPV</scp>1) Channel Blocker, on Experimental Seizures: The Roles of Cannabinoid <scp>CB</scp>1 Receptors and <scp>TRPV</scp>1 Channels. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 330-334.	1.2	20

#	Article	IF	Citations
37	Neuroinflammation as a possible link between cannabinoids and addiction. Acta Neuropsychiatrica, 2014, 26, 334-346.	1.0	18
38	Anti-aversive role of the endocannabinoid system in the periaqueductal gray stimulation model of panic attacks in rats. Psychopharmacology, 2015, 232, 1545-1553.	1.5	18
39	Orchestrated activation of mGluR5 and CB1 promotes neuroprotection. Molecular Brain, 2016, 9, 80.	1.3	18
40	Role of endocannabinoid signalling in the dorsolateral periaqueductal grey in the modulation of distinct panic-like responses. Journal of Psychopharmacology, 2015, 29, 335-343.	2.0	14
41	Inhibition of CSF1R, a receptor involved in microglia viability, alters behavioral and molecular changes induced by cocaine. Scientific Reports, 2021, 11, 15989.	1.6	14
42	Involvement of TRPV1 channels in the periaqueductal grey on the modulation of innate fear responses. Acta Neuropsychiatrica, 2015, 27, 97-105.	1.0	12
43	Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment. Epilepsy and Behavior, 2021, 121, 106832.	0.9	12
44	Hypothalamic endocannabinoid signalling modulates aversive responses related to panic attacks. Neuropharmacology, 2019, 148, 284-290.	2.0	11
45	The Endocannabinoid System Activation as a Neural Network Desynchronizing Mediator for Seizure Suppression. Frontiers in Behavioral Neuroscience, 2020, 14, 603245.	1.0	11
46	TRPV1 blockers as potential new treatments for psychiatric disorders. Behavioural Pharmacology, 2022, 33, 2-14.	0.8	11
47	Inhibition of the dopamine transporter as an animal model of bipolar disorder mania: Locomotor response, neuroimmunological profile and pharmacological modulation. Journal of Psychiatric Research, 2018, 102, 142-149.	1.5	10
48	Lack of effects of clomipramine on Fos and NADPH-diaphorase double-staining in the periaqueductal gray after exposure to an innate fear stimulus. Physiology and Behavior, 2008, 94, 316-321.	1.0	9
49	Systematic review and meta-analysis on the role of mitochondrial cytochrome c oxidase in Alzheimerâ€™s disease. Acta Neuropsychiatrica, 2021, 33, 55-64.	1.0	9
50	Role of Endocannabinoid System in the Peripheral Antinociceptive Action of Aripiprazole. Anesthesia and Analgesia, 2019, 129, 263-268.	1.1	8
51	Evaluation of Brain Cytokines and the Level of Brain-Derived Neurotrophic Factor in an Inflammatory Model of Depression. NeuroImmunoModulation, 2020, 27, 87-96.	0.9	8
52	2-Arachidonoylglycerol endocannabinoid signaling coupled to metabotropic glutamate receptor type-5 modulates anxiety-like behavior in the rat ventromedial prefrontal cortex. Journal of Psychopharmacology, 2017, 31, 740-749.	2.0	7
53	Peripheral Antinociception Induced by Aripiprazole Is Mediated by the Opioid System. BioMed Research International, 2017, 2017, 1-6.	0.9	7
54	Effects of aripiprazole on caffeine-induced hyperlocomotion and neural activation in the striatum. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 11-16.	1.4	6

#	Article	IF	Citations
55	Effects of alprazolam and cannabinoid-related compounds in an animal model of panic attack. Behavioural Brain Research, 2017, 317, 508-514.	1.2	6
56	Role of gut microbiota in the GBR12909 model of mania-like behavior in mice. Journal of Neuroimmunology, 2020, 346, 577292.	1.1	6
57	The endocannabinoid system and drug-associated contextual memories. Behavioural Pharmacology, 2022, 33, 90-104.	0.8	6
58	Cannabinoid CB1 receptors mediate the anxiolytic effects induced by systemic alprazolam and intra-periaqueductal gray 5-HT1A receptor activation. Neuroscience Letters, 2019, 703, 5-10.	1.0	5
59	Cannabidiol prevents lipopolysaccharide-induced sickness behavior and alters cytokine and neurotrophic factor levels in the brain. Pharmacological Reports, 2021, 73, 1680-1693.	1.5	5
60	Effects of the monoamine stabilizer (â^')-OSU6162 on locomotor and sensorimotor responses predictive of antipsychotic activity. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 761-768.	1.4	4
61	Protective role of endocannabinoid signaling in an animal model of haloperidol-induced tardive dyskinesia. Pharmacology Biochemistry and Behavior, 2021, 206, 173193.	1.3	4
62	Role of cytokine and neurotrophic factors in nicotine addiction in the conditioned place preference paradigm. Neuroscience Letters, 2021, 764, 136235.	1.0	4
63	Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity. Behavioural Pharmacology, 2021, 32, 2-8.	0.8	2
64	The antipsychotic aripiprazole induces peripheral antinociceptive effects through PI3KÎ³/NO/cGMP/K_{ATP} pathway activation. European Journal of Pain, 2022, 26, 825-834.	1.4	2
65	Anti-aversive effect of 2-arachidonoylglycerol in the dorsolateral periaqueductal gray of male rats in contextual fear conditioning and Vogel tests. Behavioural Pharmacology, 2022, 33, 213-221.	0.8	1
66	Effects of the monoamine stabilizer, (-)-OSU6162, on cocaine-induced locomotion and conditioned place preference in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 1143-1152.	1.4	1
67	Intravenous doxapram administration as a potential model of panic attacks in rats. Behavioural Pharmacology, 2021, 32, 182-193.	0.8	0